Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

Özgenç, Emre; Karpuz, Merve; Arzuk, Ege; González‐Álvarez, Marta; Sanz, Marival Bermejo; Gündoğdu, Evren; González‐Álvarez, Isabel

doi:10.1021/acsomega.2c03023

Cited by 12 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in cell incorporation studies in cancer cells using [ 99m Tc]NaTcO 4 as a control group, it was observed that the uptake of [ 99m Tc]NaTcO 4 was found to be approx. 60% in MCF-7 (breast cancer cell line) cells, 50% in MDA-MB-231 (triple negative breast cancer cell line) cells at 120 min . Although it was observed that [ 99m Tc]NaTcO 4 also showed uptake in cancer cells, in our study, it was observed that the radiolabeled niosome formulation showed much higher uptake than the control group.…”

Section: Resultscontrasting

confidence: 61%

See 1 more Smart Citation

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

et al. 2023

View full text Add to dashboard Cite

The aim of this research was to develop technetium-99m ([99mTc]Tc)-radiolabeled niosomes and evaluate the cancer cell incorporation capacity of radiolabeled niosomes. For this purpose, niosome formulations were developed by film hydration method, and prepared niosomes were characterized to particle size, polydispersity index (PdI), ζ-potential value, and image profile. Then, niosomes were radiolabeled with [99mTc]Tc using stannous salts (chloride) as a reducing agent. The radiochemical purity (RP) and stability in different mediums of the niosomes were assessed by ascending radioactive thin-layer chromatography (RTLC) and radioactive ultrahigh-performance liquid chromatography (R-UPLC) methods. Also, the partition coefficient value of radiolabeled niosomes was determined. The cell incorporation of [99mTc]Tc-labeled niosome formulations, as well as reduced/hydrolyzed (R/H)-[99mTc]NaTcO4 in the HT-29 (human colorectal adenocarcinoma) cells, was then assessed. According to the obtained results, the spherical niosomes had a particle size of 130.5 ± 1.364 nm, a PdI value of 0.250 ± 0.023, and a negative charge of −35.4 ± 1.06 mV. The niosome formulations were effectively radiolabeled with [99mTc]Tc using 500 μg mL–1 stannous chloride for 15 min, and RP was found to be over 95%. [99mTc]Tc-niosomes showed good in vitro stability in every system for up to 6 h. The log P value of radiolabeled niosomes was found as −0.66 ± 0.02. Compared to R/H-[99mTc]NaTcO4 (34.18 ± 1.56%), the incorporation percentages of [99mTc]Tc-niosomes (88.45 ± 2.54%) were shown to be higher in cancer cells. In conclusion, the newly developed [99mTc]Tc-niosomes showed good prototype for potential use in nuclear medicine imaging in the near future. However, further investigations, such as drug encapsulation and biodistribution studies, should be performed, and our studies are continuing.

show abstract

Section: Resultscontrasting

confidence: 61%

“…60% in MCF-7 (breast cancer cell line) cells, 50% in MDA-MB-231 (triple negative breast cancer cell line) cells at 120 min. 49 Although it was observed that [ 99m Tc]NaTcO 4 also showed uptake in cancer cells, in our study, it was observed that the radiolabeled niosome formulation showed much higher uptake than the control group.…”

Section: Resultscontrasting

confidence: 61%

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A steroidal saponin called polyphyllin D (PD) is derived from the Paris polyphylla . In certain malignancies, it induces apoptosis . Its applications are limited because it causes hemolysis .…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…It binds to the HER2 protein and prevents epidermal growth factor from entering cancer cells, preventing cell division and destruction of the immune system. TRZ can prolong the progression-free survival time of HER2-positive metastatic BC patients and is radiolabeled with 99 mTc for disease diagnosis . Using high-shear homogenization and sonication techniques, researchers developed radiolabeled TRZ-loaded SLNs found to be less than 100 nm in size with a negatively charged zeta potential.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

“…TRZ-SLNs were biocompatible and effectively induced apoptosis in the MCF-7 cells. The parenteral injection of TRZ-SLNs in rats uncovered their biocompatibility and sustained release profile in blood circulation compared to free drug solutions . Furthermore, based on characterizations, in vitro cytotoxicity, and in vivo investigations, the 99 mTc-radiolabeled TRZ-loaded SLNs could be a potential theranostic tool in treating BC.…”

Section: Therapeutic Interventions Involving Nanocarriers For Managem...mentioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

Rahman,

Afzal,

Ullah

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin cancer, BC is the second most common type of cancer in women. At the end of 2040, the number of newly diagnosed BC cases is projected to increase by over 40%, reaching approximately 3 million worldwide annually. The hormonal and chemotherapeutic approaches based on conventional formulations have inappropriate therapeutic effects and suboptimal pharmacokinetic responses with nonspecific targeting actions. To overcome such issues, the use of nanomedicines, including liposomes, nanoparticles, micelles, hybrid nanoparticles, etc., has gained wider attention in the treatment of BC. Smaller dimensional nanomedicine (especially 50–200 nm) exhibited improved in vivo effectiveness, such as better tissue penetration and more effective tumor suppression through enhanced retention and permeation, as well as active targeting of the drug. Additionally, nanotechnology, which further extended and developed theranostic nanomedicine by incorporating diagnostic and imaging agents in one platform, has been applied to BC. Furthermore, hybrid and theranostic nanomedicine has also been explored for gene delivery as anticancer therapeutics in BC. Moreover, the nanocarriers’ size, shape, surface charge, chemical compositions, and surface area play an important role in the nanocarriers’ stability, cellular absorption, cytotoxicity, cellular uptake, and toxicity. Additionally, nanomedicine clinical translation for managing BC remains a slow process. However, a few cases are being used clinically, and their progress with the current challenges is addressed in this Review. Therefore, this Review extensively discusses recent advancements in nanomedicine and its clinical challenges in BC.

show abstract

^99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis

Karpuz,

Aydin,

Ozgenc

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Inflammatory diseases including rheumatoid arthritis are major health problems. Although different techniques and drugs are clinically available for the diagnosis and therapy of the disease, novel approaches regarding radiolabeled drug delivery systems are researched. Hence, in the present study, it was aimed to design, prepare, and characterize 99mTc‐radiolabeled and tofacitinib citrate‐encapsulated microsphere loaded poloxamer in situ gel formulations for the intra‐articular treatment. Among nine different microsphere formulations, MS/TOFA‐9 was chosen as the most proper one due to particle size, high encapsulation efficiency, and in vitro drug release behavior. Poloxamer 338 at a concentration of 15% was used to prepare in situ gel formulations. For intra‐articular administration, microspheres were dispersed in an in situ gel containing 15% Poloxamer 338 and characterized in terms of gelation temperature, viscosity, rheological, mechanical, and spreadability properties. After the determination of the safe dose for MS/TOFA‐9 and PLX‐MS/TOFA‐9 as 40 µL/mL in the cell culture study performed on healthy cells, the high anti‐inflammatory effects were due to significant cellular inhibition of fibroblasts. In the radiolabeling studies with 99mTc, the optimum radiolabeling condition was determined as 200 ppm SnCl2 and 0.5 mg ascorbic acid, and both 99mTc‐MS/TOFA‐9 and 99mTc‐PLX‐MS/TOFA‐9 exhibited high cellular binding capacity. In conclusion, although further in vivo experiments are required, PLX‐MS/TOFA‐9 was found to be a promising agent for intra‐articular injection in rheumatoid arthritis.

show abstract

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

Cited by 12 publications

References 48 publications

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

^99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis

Contact Info

Product

Resources

About

Radiolabeled Trastuzumab Solid Lipid Nanoparticles for Breast Cancer Cell: in Vitro and in Vivo Studies

Cited by 12 publications

References 48 publications

[99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

[99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges

99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis

Contact Info

Product

Resources

About

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

[^99mTc]Technetium-Labeled Niosomes: Radiolabeling, Quality Control, and In Vitro Evaluation

^99mTc‐labeled, tofacitinib citrate encapsulated chitosan microspheres loaded in situ gel formulations for intra‐articular treatment of rheumatoid arthritis